SCHEMBL18608342

SCHEMBL18608342

C#Cc1ccc(NC(=O)c2cnc3cccc(C)n3c2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.48
MAPT P10636 2/20 0.47
NPC1 O15118 7/20 0.47
HSD17B10 Q99714 7/20 0.47
HPGD P15428 5/20 0.47
GAA P10253 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
RAB9A P51151 6/20 0.47
PKM P14618 1/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 1/20 0.46
GPR6 P46095 1/20 0.44
THRB P10828 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
NR3C1 P04150 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9130823 0.86 SMN1; SMN2 (0.58) MAPTNPC1HSD17B10HPGDGAA
SCHEMBL9131206 0.85 SMN1; SMN2 (0.50) MAPTNPC1HSD17B10HPGDGAA
SCHEMBL9595033 0.85 NPC1 (0.49) MAPTNPC1HSD17B10HPGDGAA
SCHEMBL18608415 0.80 MAPT (0.56) MAPTNPC1GAAMEN1KMT2A
SCHEMBL18608559 0.80 NPC1 (0.53) MAPTNPC1HSD17B10HPGDGAA
SCHEMBL18608548 0.80 NPC1 (0.48) GBA1MAPTNPC1HSD17B10HPGD
SCHEMBL18608343 0.79 NR3C1 (0.50) MAPTNPC1HSD17B10HPGDGAA
SCHEMBL18608346 0.79 SMN1; SMN2 (0.46) MAPTNPC1HSD17B10HPGDGAA
SCHEMBL9128642 0.78 HPGD (0.44) MAPTNPC1HSD17B10HPGDGAA
SCHEMBL18608550 0.77 NPC1 (0.69) MAPTNPC1HSD17B10HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190112316-A1 THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY LYSOSOMAL THERAPEUTICS INC (US) 2019-04-18 US disclosed
WO-2017040879-A1 THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY LYSOSOMAL THERAPEUTICS INC. (US) 2017-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190112316-A1 THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY PARK7, GAA, TYMP GBA1 5/4885MAPT 116/4885NPC1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.